Terms and conditions: Semantic complexity and aspirin resistance

Circulation

Volumn 110, Issue 12, 2004, Pages 1706-1708

  Hennekens, Charles H ^a,e   Schror, Karsten ^b   Weisman, Steven ^c   FitzGerald, Garret A ^d  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c Innovative Science Solutions   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e PH A   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

ARTICLE; CARDIOVASCULAR DISEASE; DRUG EFFICACY; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS; TREATMENT FAILURE;

ASPIRIN; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CYCLOOXYGENASE INHIBITORS; DRUG INTERACTIONS; DRUG RESISTANCE; FOLLOW-UP STUDIES; HUMANS; PATIENT COMPLIANCE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RISK; THROMBOXANE A2; THROMBOXANE B2; TREATMENT FAILURE; VARIATION (GENETICS);

EID: 3242716313     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000142056.69970.DB     Document Type: Article

References (24)

1. Weber AA, Przytulski B, Schanz A, et al. Towards a definition of aspirin resistance: a typological approach. Platelets. 2002;13:37-40.
2. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA. 1997;278:313-321.
3. Hennekens CH, Albert CM, Godfried SL, et al. Adjunctive drug therapy of acute myocardial infarction: evidence from clinical trials. N Engl J Med. 1996;335:1660-1667.
4. Davies MJ. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation. 1996;94: 2013-2020.
5. Halcox JP, Schenke WH, Zalos G, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation. 2002;106:653-658.
6. Sarma J, Laan CA, Alam S, et al. Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation. 2002;105: 2166-2171.
7. Sdringola S, Nakagawa K, Nakagawa Y, et al. Combined intense lifestyle and pharmacologic lipid treatment further reduce coronary events and myocardial perfusion abnormalities compared with usual-care cholesterol-lowering drugs in coronary artery disease. J Am Coll Cardiol. 2003; 41:263-272.
8. Feng DL, Murillo J, Jadhav P, et al. Upright posture and maximal exercise increase platelet aggregability and prostacyclin production in healthy male subjects. Br J Sports Med. 1999;33:401-404.
9. Muller JE, Tofler GH, Willich SN, Stone PH. Circadian variation of cardiovascular disease and sympathetic activity. J Cardiovasc Pharmacol. 1987;10(suppl 2):S104-S111.
10. FitzGerald GA, Oates JA, Hawiger J, et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest. 1983;71:676-688.
11. FitzGerald GA. Parsing an enigma: the pharmacodynamics of aspirin resistance. Lancet. 2003;361:542-544.
12. Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA. 1975;72:3073-3076.
13. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982;69:1366-1372.
14. Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood. 1987;69:180-186.
15. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J. 2001;15:2057-2072.
16. Howard PA. Aspirin resistance. Ann Pharmacother. 2002;36:1620-1624.
17. Hart RG, Leonard AD, Talbert RL, et al. Aspirin dosage and thromboxane synthesis in patients with vascular disease. Pharmacotherapy. 2003;23:579-584.
18. Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105:1650-1655.
19. Halushka MK, Walker LP, Halushka PV. Genetic variation in cyclooxygenase I: effects on response to aspirin. Clin Pharmacol Ther. 2003; 73:122-130.
20. Cambria-Kiely JA, Gandhi PJ. Aspirin resistance and genetic polymorphisms. J Thromb Thrombolysis. 2002;14:51-58.
21. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345: 1809-1817.
22. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001;88:230-235.
23. Hennekens CH, Buring JE. Epidemiology in Medicine. Boston: Little, Brown and Company; 1987.
24. FitzGerald GA. Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol. 1991;68:11B-15B.